Skip to main
PCVX

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte is in a strong position as its lead vaccine candidate, VAX-31 for PCV, has a high probability of success with an efficient and precise coupling technology. Its broad spectrum design targets serotypes in circulation associated with high case-fatality rates, antibiotic resistance, and meningitis, addressing clinically and commercially relevant gaps. With a strong financial position and multiple potential catalysts in the near-term, Vaxcyte presents a promising investment opportunity in the competitive vaccine market.

Bears say

Vaxcyte is facing potential challenges with the recent CDC decision to recommend fewer vaccines, as it could lead to decreased demand and usage of their products. Additionally, the company's current pipeline has several novel vaccines in development, which may face competition when they become established. Finally, the success of their lead candidate VAX-31 may depend on strict immunogenicity criteria, potentially hindering future competitors.

Vaxcyte (PCVX) has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Buy based on their latest research and market trends.

According to 4 analysts, Vaxcyte (PCVX) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.